Hyde Park Capital Facilitates Strategic Investment in Valley Vital by RF Investment Partners

On January 22, 2025, Hyde Park Capital proudly announced its successful guidance of RF Investment Partners, a prominent private investment firm, in securing a majority stake in Valley Infusion, LLC and Home Infusion Richmond, LLC, collectively known as Valley Vital. This strategic investment underscores RF Investment Partners' commitment to enhancing healthcare services through innovative infusion therapy solutions across Virginia and West Virginia.

Valley Vital stands out as a leader in the infusion therapy sector, operating multiple infusion pharmacies across four regions. These pharmacies aim to provide comprehensive infusion therapy solutions, catering to both chronic and acute conditions. Patients can receive quality care either in personalized home settings or specialized infusion suites. This arrangement ultimately elevates patient care, keeping comfort and accessibility at its core.

Hyde Park Capital served as the buyside investment banker for RF Investment Partners, emphasizing their adeptness in facilitating significant transactions in the healthcare domain. With over 160 infusion pharmacy locations in operation, Vital Care leads the franchise network, assuring the delivery of safe and effective infusion therapies tailored to each patient’s needs.

This collaboration brings forth several enhancements in resource allocation, patient care, and the introduction of novel infusion therapies. By expanding into West Virginia, Valley Vital aims to broaden its treatment reach and geographical footprint significantly.

RF Investment Partners proudly partners with existing management team members, CEO Preston Estep, Pharm.D., and COO Stefan Debski, Pharm.D., ensuring continuity while welcoming industry veterans Missy Coleman and Rafat Ansari to its management team. The merger promises improved accessibility to crucial infusion therapies and expanded patient care options, emphasizing a focus on healthcare delivered in familiar environments.

As Collin Abert, Managing Director at RF, articulated, “We’re enthusiastic about collaborating with the Vital Care team to usher in the next phase of their growth journey.” The partnership, pivoted on quality patient-centered care, aligns seamlessly with RF's investment principles, demonstrating a shared vision of excellence.

The insight from Michael Johnson, Managing Director at Hyde Park Capital, highlights the privilege of working alongside RF throughout this significant venture, underscoring their strategic vision for the quickly expanding infusion therapy sector. This collaboration not only fortifies Valley Vital’s market presence but also optimally positions the company for sustainable growth in delivering innovative and patient-centered infusion therapies.

Valley Vital's roots go deep, founded in 2014 and 2019, respectively. The organization brings expertise in cutting-edge infusion treatments to their West Virginia and Virginia markets. Their dual focus on in-home and clinic-based services fills a crucial gap in healthcare, especially for patients requiring acute or specialized infusion therapies.

The partnership concludes with an optimistic future as Valley Vital gears up to accelerate organic growth and acquisitions, further consolidating its market leadership in infusion therapy. As healthcare demands evolve, the commitment from both RF Investment Partners and Valley Vital stands as a beacon of progress in enhancing patient outcomes across the regions they serve.

To discover more about Valley Vital and its services, visit valleyvitalcare.com. Further insights on RF Investment Partners can also be found at rfinv.com. Additionally, for more on Hyde Park Capital, check out hydeparkcapital.com.